Critical Illness Myopathy: A Comprehensive Guide to Medical Diagnosis

Critical Illness Myopathy (CIM), frequently referred to as Intensive Care Unit (ICU) myopathy, represents a significant complication in severely ill patients. This condition manifests as generalized muscle weakness affecting the limbs, trunk, and respiratory system, contributing to increased morbidity and mortality. As a leading cause of ICU-acquired weakness, CIM is characterized by flaccid quadriparesis, predominantly impacting proximal limb muscles more severely than distal ones. Notably, sensation remains intact, distinguishing CIM from other ICU-related neuropathies such as Critical Illness Polyneuropathy (CIP) and Critical Illness Polyneuromyopathy (CIPNM). Historically, CIM has also been known by various names including acute quadriplegic myopathy (AQM), acute illness myopathy, and myopathy associated with thick filament (myosin) loss, all highlighting the core feature of muscle weakness in the critically ill. Understanding the nuances of Cim Medical Diagnosis is crucial for effective management and improved patient outcomes.

Unraveling the Etiology of Critical Illness Myopathy

The precise cause of CIM remains elusive, with most cases arising from a combination of factors. The underlying pathophysiology is intricate, involving a cascade of events at the microcirculatory level, metabolic shifts, alterations in muscle electrical properties affecting excitation-contraction coupling, and ultimately, energetic failure due to mitochondrial dysfunction. These complex interactions contribute to the development of muscle weakness characteristic of CIM.

Epidemiology and Risk Factors: Identifying Vulnerable Populations

Critical illness myopathy, along with CIP and CIPNM, is estimated to affect a substantial proportion of critically ill patients, ranging from 25% to 83%. Several risk factors have been identified that increase susceptibility to CIM. These include:

• Sepsis: Systemic infection leading to widespread inflammation.
• Multi-organ failure: Dysfunction of two or more organ systems.
• Acute Respiratory Distress Syndrome (ARDS): Severe lung injury causing respiratory failure.
• Prolonged intubation: Extended period of mechanical ventilation.
• Lengthy ICU stay: Extended time spent in the intensive care unit.
• Prolonged immobilization: Lack of physical activity during critical illness.
• Malnutrition: Inadequate nutritional intake.
• Female gender: Women may have a higher risk.
• Older age: Advanced age increases vulnerability.
• Impaired glucose homeostasis: Problems regulating blood sugar levels.
• Use of catecholamines: Medications that stimulate the sympathetic nervous system.
• Aminoglycoside antibiotics: A class of antibiotics with potential neuromuscular side effects.

While the impact of modifying these risk factors on CIM prevention is still under investigation, it’s recognized that even without glucocorticoid exposure, neuromuscular blocking agents can contribute to neuromuscular dysfunction in critically ill patients. The recent COVID-19 pandemic highlighted the increased risk of ICU-acquired weakness, including CIM, in patients with prolonged ICU stays due to severe COVID-19. Studies indicate that over 25% of patients mechanically ventilated for more than seven days in the ICU developed CIM, emphasizing the importance of vigilance in CIM medical diagnosis and management, particularly in post-pandemic critical care.

Patho-anatomy and Physiology: The Muscle Deterioration in CIM

Critical illness myopathy is an acute condition, although its exact onset can be difficult to pinpoint. The hallmark of CIM is severe muscle atrophy, specifically marked by a preferential loss of myosin, the primary protein of thick filaments in muscle fibers. The disease progression may initially involve ion channel dysfunction, followed by mitochondrial malfunction and membrane dysfunction, ultimately disrupting calcium (Ca2+) balance within muscle cells.

Histological examination of muscle tissue reveals significant muscle fiber atrophy and the selective disappearance of myosin thick filaments from the A bands. Disaggregated myosin monomers are present but lack normal enzymatic activity, likely due to ionic imbalances in the sarcoplasm.

Clinically, CIM manifests as generalized flaccid weakness affecting muscles throughout the body, including limbs, trunk, and cranial musculature. Myalgia or muscle tenderness is typically absent. A key clinical feature is neck flexor weakness, which strongly correlates with diaphragmatic weakness and difficulties in weaning patients from mechanical ventilation. Pupil-sparing ophthalmoparesis may occur but needs to be differentiated from other neuromuscular junction disorders. Deep tendon reflexes are usually diminished or absent.

Research has also identified impaired GLUT4 translocation to the sarcolemmal membrane as a mechanism contributing to reduced glucose supply to muscle cells in CIM. This impaired glucose transport, not rectified by insulin treatment, deprives skeletal muscle fibers, particularly glycolytic type 2 fibers, of crucial energy. Interestingly, electrical muscle stimulation has shown promise in restoring GLUT4 translocation and mitigating muscle fiber atrophy in CIM patients, offering a potential therapeutic avenue.

Disease Progression and Clinical Presentation Over Time

The typical clinical course of CIM often begins in patients who have been in the ICU for at least 7 days due to severe underlying conditions like sepsis or ARDS, leading to multi-organ failure and requiring mechanical ventilation. The generalized muscle weakness becomes apparent as the acute systemic illness subsides, often during attempts to wean the patient off the ventilator.

Recovery from acute myopathy generally occurs over 6 to 12 weeks after corticosteroid dosage is reduced or discontinued, although some patients may experience prolonged weakness lasting up to a year. Serum creatine kinase (CK) levels are usually elevated, particularly in the early stages of the disease. Electromyography (EMG) characteristically shows myopathic features, often including fibrillations, thought to result from motor endplate separation from intact muscle fiber segments. Muscle biopsy reveals varying degrees of necrosis and vacuolation, primarily affecting type 2 fibers, with the defining histological feature being a marked loss of myosin. Clinicians must be vigilant about muscle necrosis and elevated CK levels, as they can lead to myoglobinuria and subsequent renal failure.

For a definitive CIM medical diagnosis, patients must meet the criteria for ICU-acquired weakness (ICUAW) with weakness developing after the onset of critical illness. Diagnostic criteria also include:

• Sensory nerve action potential amplitudes greater than 80% of the lower limit of normal in at least two nerves.
• Needle EMG in two or more muscle groups demonstrating short-duration, low-amplitude motor unit potentials with early or normal full recruitment, with or without fibrillation potentials.
• Direct muscle stimulation showing reduced excitability (muscle-to-nerve ratio).
• Muscle histology consistent with myopathy.

Secondary Conditions, Associated Complications, and Differential Diagnosis

When evaluating patients presenting with acute neuromuscular weakness, especially those with ventilator weaning difficulties, a broad differential diagnosis is essential. Conditions affecting the motor neuron, neuromuscular junction, and muscle itself must be considered. These include:

• Critical Illness Polyneuropathy (CIP)
• Amyotrophic Lateral Sclerosis (ALS)
• Guillain-Barré syndrome (GBS)
• Sarcoidosis
• Myasthenia gravis
• Botulism toxicity
• Metabolic neuropathies
• Toxic neuropathies
• Toxic myopathies
• Neuropathies secondary to nutritional deficiencies

These conditions can all lead to prolonged intubation and flaccid muscle tone, necessitating careful differentiation. Distinguishing CIM from CIP can be challenging, particularly as they frequently co-exist as CIPNM. While some experts believe CIM is more prevalent than CIP, the key differentiating factor lies in sensory nerve involvement. CIM typically spares sensory nerves, whereas CIP affects both sensory and motor nerves, a distinction identifiable through physical examination and electrodiagnostic studies.

Complications associated with CIM are often secondary to immobility rather than the disease process itself. These include deep vein thrombosis (DVT) and pressure injuries. Therefore, preventative measures such as prophylactic anticoagulation and regular skin assessments are crucial in CIM management.

Post-mortem studies from the COVID-19 pandemic have shown myopathic changes consistent with CIM in a significant number of patients, highlighting CIM as a common diagnosis in post-mortem COVID-19 cases. SARS-CoV-2 infection can lead to neurological complications through direct or indirect viral actions. COVID-19-associated CIM may exhibit conventional CIM features alongside unique COVID-19-related myopathic changes, such as autophagic vacuoles, SARS-CoV immunostaining-positive granules, variable inflammation, and additional mitochondrial abnormalities. This underscores the evolving understanding of CIM medical diagnosis in the context of novel infectious diseases.

Essentials of Assessment for Accurate CIM Medical Diagnosis

History Taking

In ICU settings, patients with neuromuscular weakness are often identified due to difficulties in weaning from mechanical ventilation. Obtaining a detailed history from intubated and sedated patients can be challenging. However, understanding the patient’s underlying conditions and ICU course is vital to rule out other causes of muscle weakness. If the patient is conscious, important history points include:

• Prior history of weakness
• Onset and progression of current weakness
• Pattern of weakness (proximal vs. distal, symmetric vs. asymmetric)
• Swallowing difficulties
• Recently started medications
• Presence or absence of sensory complaints

Physical Examination

Patients with CIM typically present with diffuse, symmetric muscle weakness, more pronounced proximally than distally. Neck flexors and respiratory muscles are characteristically involved. Facial muscles, particularly extraocular muscles, are usually spared in CIM; facial weakness should raise suspicion for alternative diagnoses affecting bulbar function.

Muscle strength assessment, when possible, should utilize the Medical Research Council (MRC) System across 12 muscle groups. CIM patients typically score at least 4/5 on all testable muscles, or an average MRC sum score below 48. Muscle tone is generally flaccid, and sensory involvement is absent unless pre-existing neurological conditions are present. Deep tendon reflexes may be normal or reduced. A thorough physical exam might be deferred until sedation holidays or extubation allows for active patient participation.

Functional Assessment

Early functional assessment in the ICU is critical for identifying patients with suspected ICU-acquired weakness. ICUAW is a prevalent physical impairment affecting a significant proportion of ICU survivors. Early identification facilitates timely initiation of therapy. Studies have shown that a substantial percentage of ventilated patients experience disability in Activities of Daily Living (ADLs) and Instrumental ADLs at three months post-ICU, persisting in many at 12 months, regardless of pre-existing functional status.

Functional level in the ICU is significantly influenced by the patient’s underlying conditions and cognitive status. In the acute phase, self-care and bed mobility often require maximal assistance due to proximal muscle weakness and underlying illnesses. Despite residual weakness from disuse atrophy, most CIM patients eventually recover and regain functional independence or return to their pre-hospitalization functional status.

Laboratory Studies

Serum Creatine Phosphokinase (CPK) levels may be normal or mildly elevated in CIM. While high CK levels (up to 10 times normal) have been reported, such elevations should prompt investigation for rhabdomyolysis or toxic myopathies. Comprehensive laboratory evaluation is often performed to exclude other conditions, but currently, no validated biomarkers are unique to CIM. Cerebrospinal fluid (CSF) analysis is usually normal.

Imaging Studies

Neuroimaging, particularly neuraxial imaging, is often necessary to rule out other causes of weakness, such as stroke or spinal cord infarct, especially in non-communicative patients. Muscle Magnetic Resonance Imaging (MRI) using a myositis protocol can show enhancement on short-tau inversion-recovery images in cases of diffuse muscle edema. However, this finding is non-specific and can also be seen in rhabdomyolysis or inflammatory myositis. Currently, no imaging modality or finding is uniquely diagnostic for CIM.

Muscle ultrasound can assess muscle thickness and echogenicity in neuromuscular conditions. Studies suggest that increased muscle echogenicity on ultrasound is sensitive for CIM/CIP, and abnormal ultrasound findings may correlate with poorer discharge outcomes, suggesting potential prognostic utility.

Supplemental Assessment Tools: Electrodiagnostic Studies and Muscle Biopsy

Electrodiagnostic studies are crucial for CIM medical diagnosis, although technically challenging in ICU patients with altered consciousness and typically requiring symptom duration of over 3 weeks for reliable diagnosis.

Nerve Conduction Studies:

• Sensory nerve action potentials should be > 80% of the lower limit of normal in at least two nerves (unless pre-existing peripheral neuropathy or CIP is present).
• Compound muscle action potential (CMAP) amplitudes are often significantly reduced (<80% of the lower limit of normal).

Electromyography (EMG):

• Requires patient cooperation for voluntary muscle contraction.
• Motor unit action potentials (MUAPs) show short duration, low amplitude, and early or normal recruitment, with or without fibrillation potentials.

Direct Muscle Stimulation:

• Does not require patient cooperation.
• Compares CMAPs elicited by direct nerve stimulation (neCMAP) and direct muscle stimulation (mfCMAP) to differentiate myopathy from polyneuropathy.
• In polyneuropathy (like CIP), mfCMAP remains normal, and only neCMAP is reduced.
• In myopathy (like CIM), both neCMAP and mfCMAP are reduced, indicating reduced muscle membrane excitability.
• While technically challenging and not routinely performed, direct muscle stimulation can be valuable in distinguishing CIM from CIP, although management may not drastically change based solely on this differentiation in the ICU setting.

Muscle Biopsy:

• Can be helpful in confirming the diagnosis of CIM and ruling out other myopathies.
• Pathological classifications of CIM include thick filament myopathy, acute myopathy with scattered or diffuse necrosis, disuse cachectic myopathy, or rhabdomyolysis.
• Myosin loss is a characteristic finding, with some fibers showing absent adenosine triphosphatase staining.
• Studies have shown increased expression of calpain, a calcium-activated protease, suggesting abnormal intracellular calcium homeostasis in CIM pathogenesis.
• Biopsies may also reveal low glutamine levels, low protein/DNA levels, and high extracellular water content, implicating glutamine deficiency in CIM pathology.

Professional Considerations

Given the critical condition of most CIM patients and their potential inability to communicate, identifying the person with power of attorney and maintaining close communication with family members and social support networks is essential for ethical and patient-centered care.

Rehabilitation Management and Treatment Strategies

Current Treatment Guidelines and Rehabilitation Approaches

Specific rehabilitation guidelines tailored to improve functional outcomes in CIM are still evolving. Currently, there is no specific pharmacological treatment for CIM. Prevention and early recognition are paramount for improved patient outcomes. Medically, prevention focuses on minimizing risk factors and optimizing medical management of critically ill patients. Strict glycemic control, maintaining glucose levels between 80 and 110 mg/dl via insulin therapy, may reduce CIM risk.

Early rehabilitation and mobilization in the ICU are increasingly recognized as crucial for improving short-term outcomes and mitigating sequelae of deconditioning and immobility. Evidence supports initiating early mobilization soon after ICU admission to improve short-term outcomes. Neuromuscular electrical stimulation and nutritional supplementation may also be considered as adjunct therapies.

Coordination of Care

Effective CIM management requires an interdisciplinary team, including physicians, nurses, respiratory therapists, physical therapists, occupational therapists, and potentially speech therapists. Follow-up with a physiatrist and/or primary care provider should be arranged for functional reassessment 2 to 3 months post-ICU discharge to ensure ongoing recovery and management.

The COVID-19 pandemic underscored the challenges of patient communication in the ICU, potentially leading to miscommunication and poorer outcomes. Healthcare professionals and therapists have had to adapt and innovate to bridge communication gaps and maintain effective therapy and family education.

Patient and Family Education

Engaging the patient’s family and/or caregivers in rehabilitation goal setting is vital. Some ICUs utilize patient diaries to communicate information to patients and families. Emphasizing the gradual nature of recovery from CIM is important for managing expectations and fostering realistic rehabilitation goals.

Emerging Interventions

• Electrical muscle stimulation (EMS): Studies suggest EMS in CIM patients, especially those intubated and sedated, can improve muscle strength and facilitate earlier mobilization.
• Early physical therapy: Initiating physical therapy early in the ICU setting has demonstrated short-term benefits.
• Early mobility and walking programs: These programs have shown benefits for both short-term and long-term outcomes.
• Nutritional supplementation: Protein, antioxidant, and amino acid supplementation (e.g., glutamine, arginine) may aid in faster recovery from muscle catabolism associated with CIM.
• Addressing COVID-19 related gaps: The pandemic highlighted the need for improved bilingual communication modalities and timely utilization of therapy resources, especially given the increased therapy needs and delayed speaking valve transitions in post-COVID-19 patients.

Translation into Practice: Practice Pearls and Performance Improvement

Historically, bed rest was the standard in ICUs, with physical therapy delayed until after ICU discharge. However, prevention through early mobilization is increasingly recognized as a key “treatment” for CIM. Shifting ICU culture to prioritize early mobilization requires a patient-focused approach and enhanced interdisciplinary teamwork. Mobility is facilitated by an ICU culture that integrates activity as a core component of care.

Cutting Edge Concepts and Practice in CIM Management

• Early and regular mobilization of ICU patients.
• Early delivery of ICU-based physical therapy.
• Neuromuscular electrical stimulation.
• Quantitative neuromuscular ultrasound: For early evaluation of neuromuscular pathology in critical illness.
• Nutritional and hormonal therapies: Exploring the benefits of glutamine, glutathione, and hormonal supplementation.

Gaps in Evidence-Based Knowledge and Future Research Directions

• Developing effective strategies to identify patients at risk of critical illness-associated physical, psychological, and cognitive morbidities.
• Further studies to elucidate the mechanisms by which immobility and other aspects of critical illness lead to neuromuscular dysfunction and injury.
• Studies examining the preventative effects of electrical muscle stimulation.
• Comparative studies evaluating resource needs for safe ICU patient mobilization and exercise.
• Randomized controlled trials assessing early rehabilitation strategies and optimal timing during critical illness, including comparisons of ICU-based versus acute inpatient rehabilitation physical therapy.
• Prospective studies investigating long-term consequences and comorbidities associated with CIM.
• Retrospective studies examining rehabilitation effects in SARS-CoV-2 recovered patients with CIM.
• Studies assessing the financial feasibility of early mobilization in the ICU setting.

References

1. Brown D, Williams K, Cuccurullo S. Myopathies. In: Maitin IB, Cruz E. eds. CURRENT Diagnosis & Treatment: Physical Medicine & Rehabilitation. McGraw Hill; 2014. Accessed September 05, 2023. https://accessmedicine-mhmedical-com.ezaccess.libraries.psu.edu/content.aspx?bookid=1180&sectionid=70378701
2. Schweickert W, Kress JP. ICU-Acquired Weakness. In: Hall JB, Schmidt GA, Kress JP. eds. Principles of Critical Care, 4e. McGraw Hill; 2014. Accessed September 05, 2023. https://accessmedicine-mhmedical-com.ezaccess.libraries.psu.edu/content.aspx?bookid=1340&sectionid=80035955
3. Doughty, Christopher T., and Amato Anthony A. “109 Disorders of Skeletal Muscle.” Bradley and Daroff’s Neurology in Clinical Practice, 2-Volume Set, ELSEVIER – HEALTH SCIENCE, S.l., 2021.
4. Zhou C, Wu L, Ni F, Ji W, Wu J, Zhang H. Critical illness polyneuropathy and myopathy: a systematic review. Neural Regen Res. 2014;9(1):101-110. doi:10.4103/1673-5374.125337
5. Price DR, Mikkelsen ME, Umscheid CA, Armstrong EJ. Neuromuscular Blocking Agents and Neuromuscular Dysfunction Acquired in Critical Illness: A Systematic Review and Meta-Analysis. Crit Care Med. 2016 Nov;44(11):2070-2078. doi: 10.1097/CCM.0000000000001839. PMID: 27513545.
6. Dubowitz, Victor, et al. “Toxic and Drug-Induced Myopathies.” Muscle Biopsy: A Modern Approach, Ballière Tindall, London, 1985.
7. Lacomis D, Petrella JT, Guiliani MJ. Cause of neuromuscular weakness in the intensive care unit: A study of ninety-two patients. Muscle Nerve. 1998;21:610-617.
8. Connolly B, O’Neill B, Salisbury L on behalf of the Enhanced Recovery After Critical Illness Programme Group, et al Physical rehabilitation interventions for adult patients during critical illness: an overview of systematic reviews. Thorax 2016;71:881-890.
9. Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, Al Hasani H, Chadt A, Wenzel K, Koch S, Fielitz J, Kleber C, Faust K, Mai K, Spies CD, Luft FC, Boschmann M, Spranger J, Spuler S. Critical illness myopathy and GLUT4. Am J Respir Crit Care Med.2013;187(4)387-396.
10. Koch S, Wollersheim T, Bierbrauer J, Haas K, Mörgeli R, Deja M, Spies CD, Spuler S, Krebs M, Weber-Carstens S. Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy. Muscle Nerve. 2014 Sep;50(3):431-6. doi: 10.1002/mus.24175. Epub 2014 Jul 14. PMID: 24415656
11. Herridge M (2013). Chapter 68. long-term outcomes after mechanical ventilation. Tobin M.J.(Ed.), Principles and Practice of Mechanical Ventilation, 3e. McGraw Hill. https://accessmedicine-mhmedical-com.ezaccess.libraries.psu.edu/content.aspx?bookid=520&sectionid=41692317
12. Taylor, Christopher. Intensive Care Unit Acquired Weakness. Anaesthesia & Intensive Care Medicine, vol. 19, no. 3, Feb. 2018, pp. 79–82., doi:10.1016/j.mpaic.2017.12.009.
13. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve. 1997;20:316-322.
14. Latronico, Nicola; Bolton, Charles F.The Lancet Neurology;London Vol. 10, Iss. 10, (Oct 2011): 931-41.
15. Shepherd S, Batra A, Lerner DP. Review of Critical Illness Myopathy and Neuropathy. Neurohospitalist. 2017;7(1):41-48. doi:10.1177/1941874416663279
16. Bagnato, Sergio, et al. “Critical illness myopathy after COVID-19.” International Journal of Infectious Diseases, vol. 99, 2020, pp. 276–278, https://doi.org/10.1016/j.ijid.2020.07.072.
17. Dhand UK. Clinical approach to the weak patient in the intensive care unit. Resp Care. 2006;51(9):1024-1040.
18. ZʼGraggen WJ, Tankisi H. Critical Illness Myopathy. J Clin Neurophysiol. 2020 May;37(3):200-204. doi: 10.1097/WNP.0000000000000652. PMID: 32358245.
19. Vanhorebeek, I., Latronico, N. & Van den Berghe, G. ICU-acquired weakness. Intensive Care Med 46, 637–653 (2020). https://doi.org/10.1007/s00134-020-05944-4
20. Hermans G and Van den Berghe G. Clinical review: Intensive care unit acquired weakness. Critical Care. 2015;19:274.
21. Bunnell A, Ney J, Gellhorn A, Hough CL. Quantitative neuromuscular ultrasound in intensive-care acquired weakness: a systematic review. Muscle Nerve. 2015; 52:701-708.
22. Guimarães, J.B., Nico, M.A., Omond, A.G. et al. Diagnostic Imaging of Inflammatory Myopathies: New Concepts and a Radiological Approach. Curr Rheumatol Rep 21, 8 (2019). https://doi.org/10.1007/s11926-019-0807-z
23. Osias J and Manno E. Neuromuscular complications of critical illness. Crit Care Clin.2014;30:785-794.24.
24. Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve. 1997;20:665-673.
25. Lefaucheur JP, Nordine T, Rodriguez P, Brochard L. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry. 2006;77:500-506.
26. Marrero HG and Stålberg EV. Optimizing testing methods and collection of reference data for differentiating critical illness polyneuropathy from critical illness myopathies. Muscle Nerve.2016;53:555-563.
27. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidencefor calpain-mediated proteolysis. Muscle Nerve. 1997;20:316-322.
28. Hermans G, De Jonghe B, Buryninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database of Systemic Reviews. 2014;1:1-24.
29. Bird SJ. Diagnosis and management of critical illness polyneuropathy and critical illness myopathy. Curr Treat Options Neurol. 2007;9:85-92.
30. Jang MH, Shin MJ, Shin YB. Pulmonary and Physical Rehabilitation in Critically Ill Patients. Acute Crit Care. 2019;34(1):1-13. doi:10.4266/acc.2019.00444
31. Pauley, Ellen, et al. “Physical rehabilitation and critical illness.” Anaesthesia & Intensive Care Medicine, vol. 22, no. 11, 2021, pp. 690–692, https://doi.org/10.1016/j.mpaic.2021.07.021.
32. National Institute for Health and Clinical Excellence. Rehabilitation after critical illness. March 2009. Available at: http://www.nice.org.uk/CG83. Accessed October 16, 2012.
33. Scibilia, Stephanie J., et al. “Impact of COVID-19 on patient-provider communication in critical care: Case reports.” Critical Care Nurse, vol. 42, no. 4, 2022, pp. 38–46, https://doi.org/10.4037/ccn2022405.
34. Burnham EL, Moss M, Ziegler TR. Myopathies in critical illness: characterization and nutritional aspects. J Nutr. 2005;135:1818S-1823S.
35. Bailey PP, Miller RR 3rd, Clemmer TP. Culture of early mobility in mechanically ventilated patients. Crit Care Med. 2009;37(10 Suppl):S429-435.
36. Bunnell A, Ney J, Gellhorn A, Hough CL. Quantitative neuromuscular ultrasound in intensive-care acquired weakness: a systematic review. Muscle Nerve. 2015; 52:701-708.